Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody

Seattle Genetics is one step closer to getting its second armed antibody across the finish line, after the ‘breakthrough’ Astellas-partnered drug — enfortumab vedotin — helped patients with advanced or metastatic urothelial cancer, whose disease progressed despite treatment with both platinum-containing chemotherapy and a checkpoint inhibitor, in a key study.